The nice people at Oncology Central sent
their update today. Much of it went over my head, but some might have stuck…
Editor's pick |
.png?width=520&upscale=true&name=OC%20NL%20(21).png) |
JAVELIN Bladder Medley trial: avelumab-based combinations for advanced urothelial carcinoma
Our partner journal Future Oncology has recently published a Clinical Trial Protocol, which details the Phase II JAVELIN Bladder Medley umbrella trial (NCT05327530). |
Latest news |
.png?width=520&upscale=true&name=OC%20NL%20(22).png) |
Anti-CTLA-4 immunotherapy mobilizes microglia against glioblastoma
A study led by Salk Institute (CA, USA) scientists has shown that anti-CTLA-4 immunotherapy increases the survival of mice with glioblastoma. |
.png?width=520&upscale=true&name=OC%20NL%20(23).png) |
ReIMAGINE study demonstrates feasibility of MRI-enhanced prostate cancer screening
Recently published in BMJ Oncology, results from the ReIMAGINE study demonstrate the feasibility of combining MRI with PSA testing to improve the detection of prostate cancer. |
.png?width=520&upscale=true&name=OC%20NL%20(24).png) |
Gut feeling: AI tool predicts stomach cancer risk up to 3 years prior to diagnosis
AI successfully uses demographic information, medical history and routine laboratory findings to predict a patient’s risk of developing esophageal cancer up to 3 years before diagnosis. |
No comments:
Post a Comment